"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
Patients receiving activated DEFINITY® should be instructed to inform their healthcare provider if they:
- have a congenital heart defect, or recent worsening of heart or lung conditions [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS],
- have had prior reactions to DEFINITY® [see CONTRAINDICATIONS],
- may be pregnant, are trying to become pregnant, or are nursing [see Use In Specific Populations].
Last reviewed on RxList: 8/31/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Definity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.